Rekvina Laboratories Ltd. Announces Board Meeting Outcomes: Increase in Authorized Share Capital, Acquisition of Radiant Parenterals Limited, and Preferential Issue of Equity Shares

Rekvina Laboratories Ltd. held a board meeting on March 16, 2026, and approved various matters, including an increase in authorized share capital, acquisition of 100% equity shares of Radiant Parenterals Limited, and issuance of equity shares by way of preferential issue on a private placement basis for cash consideration and non-cash consideration. The acquisition of Radiant Parenterals Limited will be made at a price of ₹ 25 per equity share, amounting to ₹ 4,62,77,500. The company will issue 46,27,750 equity shares as consideration, which will be discharged by way of issuing fully paid-up equity shares of face value ₹ 5 each at a price of ₹ 10 per equity share. The proposed transaction is being undertaken on an arm's length basis and is subject to regulatory approvals. The board also approved the issuance of 46,27,750 equity shares on a preferential basis to existing shareholders of Radiant for the consideration other than cash, and the execution of the share subscription agreement. Additionally, the board approved the issuance and allotment of 4,60,000 fully paid-up equity shares to non-promoters on a preferential basis for cash consideration.